0001179110-15-009895.txt : 20150616
0001179110-15-009895.hdr.sgml : 20150616
20150616161942
ACCESSION NUMBER: 0001179110-15-009895
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20150615
FILED AS OF DATE: 20150616
DATE AS OF CHANGE: 20150616
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Celldex Therapeutics, Inc.
CENTRAL INDEX KEY: 0000744218
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 133191702
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
BUSINESS PHONE: 908-200-7500
MAIL ADDRESS:
STREET 1: 53 FRONTAGE ROAD
STREET 2: SUITE 220
CITY: HAMPTON
STATE: NJ
ZIP: 08827
FORMER COMPANY:
FORMER CONFORMED NAME: AVANT IMMUNOTHERAPEUTICS INC
DATE OF NAME CHANGE: 19980828
FORMER COMPANY:
FORMER CONFORMED NAME: T CELL SCIENCES INC
DATE OF NAME CHANGE: 19920703
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CATLIN AVERY W
CENTRAL INDEX KEY: 0001255348
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-15006
FILM NUMBER: 15934559
MAIL ADDRESS:
STREET 1: 241 CENTRAL STREET
CITY: HINGHAM
STATE: MA
ZIP: 02043
4
1
edgar.xml
FORM 4 -
X0306
4
2015-06-15
0
0000744218
Celldex Therapeutics, Inc.
CLDX
0001255348
CATLIN AVERY W
C/O CELLDEX THERAPEUTICS, INC.
53 FRONTAGE ROAD
HAMPTON
NJ
08827
0
1
0
0
Sr. VP & CFO
Common Stock
2015-06-15
4
M
0
25000
8.52
A
49609
D
Common Stock
2015-06-15
4
S
0
25000
24.5901
D
24609
D
Non-Qualified Stock Option
8.52
2015-06-15
4
M
0
25000
0
D
2010-01-06
2019-01-06
Common Stock
25000
0
D
The sale reported on this Form 4 was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12,2015. The options exercised and sold by the Reporting Person were due to expire January 6,2019.
25% of the shares vested on January 6, 2010 and the remainder vested quarterly (in equal amounts) over the subsequent 12 quarters.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.35 to $25.23, inclusive. The Reporting Person undertakes to provide to Celldex Therapeutics, Inc., any security holder of Celldex Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.
/s/ Anthony S. Marucci, attorney in fact for Avery W. Catlin
2015-06-16